Browsing by Author "Howlett, Jonathan G."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- ItemGlobal variation in quality of care among patients hospitalized with acute heart failure in an international trial: Findings from the Acute Study Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF)(2013) Howlett, Jonathan G.; Ezekowitz, Justin A.; Podder, Mohua; Hernández, Adrián F.; Díaz, Rafael; Dickstein, Kenneth; Dunlap, Mark E.; Corbalán Herreros, Ramón; Armstrong, Paul W.; Starling, Randall C.; O'Connor, Christopher M.; Califf, Robert M.; Fonarow, Gregg C .; ASCEND-HF Investigators
- ItemOmecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials(2020) Teerlink, John R.; Diaz, Rafael; Felker, G. Michael; McMurray, John J. V.; Metra, Marco; Solomon, Scott D.; Adams, Kirkwood F.; Anand, Inder; Arias-Mendoza, Alexandra; Biering-Sorensen, Tor; Bohm, Michael; Bonderman, Diana; Cleland, John G. F.; Corbalan, Ramon; Crespo-Leiro, Maria G.; Dahlstrom, Ulf; Echeverria Correa, Luis E.; Fang, James C.; Filippatos, Gerasimos; Fonseca, Candida; Goncalvesova, Eva; Goudev, Assen R.; Howlett, Jonathan G.; Lanfear, David E.; Lund, Mayanna; Macdonald, Peter; Mareev, Vyacheslav; Momomura, Shin-ichi; O'Meara, Eileen; Parkhomenko, Alexander; Ponikowski, Piotr; Ramires, Felix J. A.; Serpytis, Pranas; Sliwa, Karen; Spinar, Jindrich; Suter, Thomas M.; Tomcsanyi, Janos; Vandekerckhove, Hans; Vinereanu, Dragos; Voors, Adriaan A.; Yilmaz, Mehmet B.; Zannad, Faiez; Sharpsten, Lucie; Legg, Jason C.; Abbasi, Siddique A.; Varin, Claire; Malik, Fady I.; Kurtz, Christopher E.Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials.